Desmopressin vs alpha‐blocker
Major adverse events
1 finding from 1 review
- no estimate extracted1 study · 31 participantsLow
Findings
What do systematic reviews say?
4,918 questions · 5,537 findings · 1,803 reviews
No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Desmopressin vs alpha‐blocker
Minor adverse events
It is very uncertain whether desmopressin changes minor adverse events compared with alpha‐blocker (very low certainty).
1 finding from 1 review
- RR 1.07 [0.07, 15.57]1 study · 31 participantsVery low
Desmopressin plus alpha‐blocker vs alpha‐blocker
Major adverse events
Desmopressin plus alpha‐blocker showed no clear difference in major adverse events compared with alpha‐blocker (low certainty).
1 finding from 1 review
- RR 0.3 [0.01, 7.32]3 studies · 402 participantsLow
Desmopressin plus alpha‐blocker vs alpha‐blocker
Minor adverse events
It is very uncertain whether desmopressin plus alpha‐blocker changes minor adverse events compared with alpha‐blocker (very low certainty).
1 finding from 1 review
- RR 1.6 [0.15, 16.82]3 studies · 402 participantsVery low
Desmopressin plus alpha‐blocker vs alpha‐blocker plus anticholinergic
Major adverse events
1 finding from 1 review
- no estimate extracted1 study · 427 participantsLow
Desmopressin plus alpha‐blocker vs alpha‐blocker plus anticholinergic
Minor adverse events
Desmopressin plus alpha‐blocker may leads to lower minor adverse events compared with alpha‐blocker plus anticholinergic (low certainty).
1 finding from 1 review
- RR 0.22 [0.05, 0.98]1 study · 427 participantsLow
Alvimopan vs placebo
Major adverse events
Alvimopan probably leads to lower major adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Alvimopan for recovery of bowel function after radical cystectomy 2017 · Cochrane Headline outcomes onlyRR 0.28 [0.18, 0.44]1 study · 277 participantsModerate
Shared decision‐making (all components) vs usual care
Adverse events (all) · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Macrolides vs other antibiotics
Minor adverse events · sexually active adults
It is very uncertain whether macrolides changes minor adverse events compared with any other antibiotic (very low certainty).
1 finding from 1 review
- Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes onlyRR 1.34 [0.24, 7.51]3 studies · 412 participantsVery low
Erythromycin vs any other macrolide
Minor adverse events · sexually active adults
It is very uncertain whether macrolide (erythromycin) changes minor adverse events compared with any other macrolide (very low certainty).
1 finding from 1 review
- Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults 2017 · Cochrane Headline outcomes onlyRR 1.14 [0.63, 2.06]1 study · 101 participantsVery low
Oral tramadol vs oral morphine
Other adverse events · people with cancer pain
1 finding from 1 review
- Tramadol with or without paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
Low‐dose aspirin vs placebo or no treatment
Other adverse events · women with subfertility
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Other adverse events · patients with venous leg ulcers
1 finding from 1 review
- no estimate extracted2 studies · 71 participantsGRADE not reported
Summary of findings for the main comparison. Implantable loop recorder vs conventional diagnostic workup
Other adverse events · people with unexplained recurrent syncope
1 finding from 1 review
- Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope 2016 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 447 participantsGRADE not reported
Intervention not reported
Adverse events (AEs) · individuals with stable bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Stopping LABA vs continuing use of LABA+ICS
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
- Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes onlyOR 0.83 [0.66, 1.05]5 studies · 1339 participantsModerate
LAMA add‐on vs long‐acting beta2‐agonists (LABA) add‐on
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
- Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting… 2015 · Cochrane Headline outcomes onlyOR 1.11 [0.92, 1.35]3 studies · 1839 participantsModerate
Gait training protocol focused on impairment level vs gait training protocol focused on task level
Adverse events – pain · people with transtibial amputation due to peripheral arterial disease or diabetes
1 finding from 1 review
- Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial disease or… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 22 participantsVery low
Mycophenolate sodium + oral steroids vs oral steroids alone
Adverse events: death · minimal change disease in adults with nephrotic syndrome
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
1 finding from 1 review
- Interventions for minimal change disease in adults with nephrotic syndrome 2022 · Cochrane Headline outcomes onlyRR 0.67 [0.12, 3.84]1 study · 116 participantsLow
Berotralstat vs placebo or active control
Adverse events(during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 1.03 [0.88, 1.22]3 studies · 128 participantsModerate